Rotondo John Charles, Mazzoni Elisa, Bononi Ilaria, Tognon Mauro, Martini Fernanda
Section of Pathology, Oncology and Experimental Biology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
Front Oncol. 2019 Jul 25;9:670. doi: 10.3389/fonc.2019.00670. eCollection 2019.
Simian virus 40 (SV40) is a small DNA tumor virus of monkey origin. This polyomavirus was administered to human populations mainly through contaminated polio vaccines, which were produced in naturally infected SV40 monkey cells. Previous molecular biology and recent immunological assays have indicated that SV40 is spreading in human populations, independently from earlier SV40-contaminated vaccines. SV40 DNA sequences have been detected at a higher prevalence in specific human cancer specimens, such as the brain and bone tumors, malignant pleural mesotheliomas, and lymphoproliferative disorders, compared to the corresponding normal tissues/specimens. However, other investigations, which reported negative data, did not confirm an association between SV40 and human tumors. To circumvent the controversies, which have arisen because of these molecular biology studies, immunological researches with newly developed indirect ELISA tests were carried out in serum samples from patients affected by the same kind of tumors as mentioned above. These innovative indirect ELISAs employ synthetic peptides as mimotopes/specific SV40 antigens. SV40 mimotopes do not cross-react with the homologous human polyomaviruses, BKPyV, and JCPyV. Immunological data obtained from indirect ELISAs, using SV40 mimotopes, employed to analyze serum samples from oncological patients, have indicated that these sera had a higher prevalence of antibodies against SV40 compared to healthy subjects. The main data on (i) the biology and genetics of SV40; (ii) the epidemiology of SV40 in the general population, (iii) the mechanisms of SV40 transformation; (iv) the putative role of SV40 in the onset/progression of specific human tumors, and (v) its association with other human diseases are reported in this review.
猴病毒40(SV40)是一种源自猴子的小型DNA肿瘤病毒。这种多瘤病毒主要通过受污染的脊髓灰质炎疫苗传播给人类,这些疫苗是在自然感染SV40的猴细胞中生产的。先前的分子生物学研究和最近的免疫学检测表明,SV40正在人类群体中传播,与早期受SV40污染的疫苗无关。与相应的正常组织/标本相比,在特定的人类癌症标本中,如脑肿瘤、骨肿瘤、恶性胸膜间皮瘤和淋巴增殖性疾病中,检测到SV40 DNA序列的患病率更高。然而,其他报告阴性数据的研究并未证实SV40与人类肿瘤之间存在关联。为了避免因这些分子生物学研究而产生的争议,对上述同类肿瘤患者的血清样本进行了新开发的间接ELISA检测的免疫学研究。这些创新的间接ELISA使用合成肽作为模拟表位/特异性SV40抗原。SV40模拟表位不会与同源的人类多瘤病毒BKPyV和JCPyV发生交叉反应。使用SV40模拟表位的间接ELISA获得的免疫学数据,用于分析肿瘤患者的血清样本,结果表明,与健康受试者相比,这些血清中抗SV40抗体的患病率更高。本综述报告了关于(i)SV40的生物学和遗传学;(ii)普通人群中SV40的流行病学;(iii)SV40转化的机制;(iv)SV40在特定人类肿瘤发生/进展中的假定作用;以及(v)其与其他人类疾病的关联的主要数据。